(2R)-1-[4-(4-chlorocyclohexa-2,4-dien-1-yl)oxy-3,5-difluorophenyl]sulfonyl-4-[5-(dimethylamino)naphthalen-1-yl]sulfonyl-N-hydroxypiperazine-2-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (2R)-1-[4-(4-chlorocyclohexa-2,4-dien-1-yl)oxy-3,5-difluorophenyl]sulfonyl-4-[5-(dimethylamino)naphthalen-1-yl]sulfonyl-N-hydroxypiperazine-2-carboxamide
• 化学式: C₂₉H₂₉ClF₂N₄O₇S₂
• 分子量: 683.1
• InChiKey: RRSQMKGMNHIBGB-COTLDPOVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  45
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  153
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• [EN] SELECTIVE MMP INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE MMP
  申请人：SYMPHONY EVOLUTION INC

  公开号：WO2014028334A1

  公开（公告）日：2014-02-20

  Described are methods for treating diseases by use of agents that selectively inhibit human metalloproteinases (MMP), such as MMP-9 and MMP-2, while optionally sparing MMP-1. Prevention of atherosclerotic plaque development and rupture and/or carotid arterial plaque development and rupture, by MMP inhibition can reduce the adverse consequences of plaque development and rupture including thromboembolism, stroke, myocardial infarction and acute coronary syndromes.